- Home
- LDTC vs ENSC Comparison
LDTC vs ENSC Comparison
Compare LDTC & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- ENSC
- Stock Information
- Founded
- LDTC 2007
- ENSC 2003
- Country
- LDTC Canada
- ENSC United States
- Employees
- LDTC N/A
- ENSC N/A
- Industry
- LDTC Blank Checks
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- ENSC Health Care
- Exchange
- LDTC Nasdaq
- ENSC Nasdaq
- Market Cap
- LDTC 10.6M
- ENSC 9.5M
- IPO Year
- LDTC N/A
- ENSC N/A
- Fundamental
- Price
- LDTC $1.01
- ENSC $6.07
- Analyst Decision
- LDTC Buy
- ENSC
- Analyst Count
- LDTC 3
- ENSC 0
- Target Price
- LDTC $3.00
- ENSC N/A
- AVG Volume (30 Days)
- LDTC 21.8M
- ENSC 154.9K
- Earning Date
- LDTC 12-18-2024
- ENSC 11-12-2024
- Dividend Yield
- LDTC N/A
- ENSC N/A
- EPS Growth
- LDTC N/A
- ENSC N/A
- EPS
- LDTC N/A
- ENSC N/A
- Revenue
- LDTC $353,686.00
- ENSC $4,421,404.00
- Revenue This Year
- LDTC N/A
- ENSC N/A
- Revenue Next Year
- LDTC $9.55
- ENSC N/A
- P/E Ratio
- LDTC N/A
- ENSC N/A
- Revenue Growth
- LDTC 141.86
- ENSC 40.41
- 52 Week Low
- LDTC $0.22
- ENSC $2.12
- 52 Week High
- LDTC $9.99
- ENSC $30.90
- Technical
- Relative Strength Index (RSI)
- LDTC 53.75
- ENSC 42.77
- Support Level
- LDTC $1.05
- ENSC $5.34
- Resistance Level
- LDTC $2.05
- ENSC $8.27
- Average True Range (ATR)
- LDTC 0.34
- ENSC 1.06
- MACD
- LDTC 0.06
- ENSC -0.24
- Stochastic Oscillator
- LDTC 30.12
- ENSC 18.43
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.